The link between abnormal TRPV2 expression and cancer progression has been widely studied and TRPV2 seems to exhibit oncogenic activity in cancers of the prostate and breast, as well as in esophageal squamous cell carcinoma, leukemia, multiple myeloma and glioblastomas [82,221,222,223]. This evidence concerns the gene TRPV2 and plasma cell myeloma.